Literature DB >> 29947726

Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation.

Rishi J Desai1, Richard Wyss1, Yinzhu Jin1, Justin Bohn1, Sengwee Toh2, Austin Cosgrove2, Adee Kennedy2, Jessica Kim3, Clara Kim3, Rita Ouellet-Hellstrom4, Sara Karami4, Jacqueline M Major4, Aaron Niman4, Shirley V Wang1, Joshua J Gagne1.   

Abstract

Use of disease risk score (DRS)-based confounding adjustment when estimating treatment effects on multiple outcomes is not well studied. We designed an empirical cohort study to compare dabigatran initiators and warfarin initiators with respect to risks of ischemic stroke and major bleeding in 12 sequential monitoring periods (90 days each), using data from the Truven Marketscan database (Truven Health Analytics, Ann Arbor, Michigan). We implemented 2 approaches to combine DRS for multiple outcomes: 1) 1:1 matching on prognostic propensity scores (PPS), created using DRS for bleeding and stroke as independent variables in a propensity score (PS) model; and 2) simultaneous 1:1 matching on DRS for bleeding and stroke using Mahalanobis distance (M-distance), and compared their performance with that of traditional PS matching. M-distance matching appeared to produce more stable results in the early marketing period than both PPS and traditional PS matching; hazard ratios from unadjusted analysis, traditional PS matching, PPS matching, and M-distance matching after 4 periods were 0.72 (95% confidence interval (CI): 0.51, 1.03), 0.61 (95% CI: 0.31, 1.09), 0.55 (95% CI: 0.33, 0.91), and 0.78 (95% CI: 0.45, 1.34), respectively, for stroke and 0.65 (95% CI: 0.53, 0.80), 0.78 (95% CI: 0.60, 1.01), 0.75 (95% CI: 0.59, 0.96), and 0.78 (95% CI: 0.64, 0.95), respectively, for bleeding. In later periods, estimates were similar for traditional PS matching and M-distance matching but suggested potential residual confounding with PPS matching. These results suggest that M-distance matching may be a valid approach for extension of DRS-based confounding adjustments for multiple outcomes of interest.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29947726     DOI: 10.1093/aje/kwy130

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  6 in total

1.  Standardizing Discrete-Time Hazard Ratios With a Disease Risk Score.

Authors:  David B Richardson; Alexander P Keil; Jessie K Edwards; Alan C Kinlaw; Stephen R Cole
Journal:  Am J Epidemiol       Date:  2020-10-01       Impact factor: 4.897

2.  Health Effects of Religion, Spirituality, and Supernatural Beliefs in Mainland China: A Systematic Review.

Authors:  Stephen W Pan; Yuxin Liang; Shiqiang Wu; Wanqi Wang; Xinwen Hu; Jing Wang; Wenting Huang
Journal:  J Relig Health       Date:  2022-03-26

3.  Disparities by sex in P2Y12 inhibitor therapy duration, or differences in the balance of ischaemic-benefit and bleeding-risk clinical outcomes in older women versus comparable men following acute myocardial infarction? A P2Y12 inhibitor new user retrospective cohort analysis of US Medicare claims data.

Authors:  Ryan P Hickson; Anna M Kucharska-Newton; Jo E Rodgers; Betsy L Sleath; Gang Fang
Journal:  BMJ Open       Date:  2021-12-01       Impact factor: 2.692

4.  Association of injury after prescription opioid initiation with risk for opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case-control study.

Authors:  Yu-Jung Jenny Wei; Cheng Chen; Ting-Yuan David Cheng; Siegfried O Schmidt; Roger B Fillingim; Almut G Winterstein
Journal:  PLoS Med       Date:  2022-09-22       Impact factor: 11.613

5.  Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children.

Authors:  Yun-Han Wang; Viktor Wintzell; Jonas F Ludvigsson; Henrik Svanström; Björn Pasternak
Journal:  JAMA Pediatr       Date:  2020-06-01       Impact factor: 16.193

6.  Surgical necrotizing enterocolitis but not spontaneous intestinal perforation is associated with adverse neurological outcome at school age.

Authors:  Alexander Humberg; Juliane Spiegler; Mats Ingmar Fortmann; Michael Zemlin; Janina Marissen; Isabelle Swoboda; Tanja K Rausch; Egbert Herting; Wolfgang Göpel; Christoph Härtel
Journal:  Sci Rep       Date:  2020-02-11       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.